Cobos LD, Fierro AL, Arellano MI, Bonifaz A

Idioma: Español
Referencias bibliográficas: 58
Paginas: 318-327
Archivo PDF: 161.46 Kb.

RESUMEN

La onicomicosis es la infección ungueal más frecuente y crónica. Es causada por una gran variedad de microorganismos, la mayoría de ellos dermatofitos. Esta enfermedad puede tener un efecto negativo y significativo en la calidad de vida de los pacientes, tanto a nivel fisiológico como emocional, incluso puede causar estigmatización y exclusión social. Los cambios ungueales pueden causar dolor al caminar o al permanecer de pie durante largos periodos, con limitación de la movilidad o de realizar ciertas actividades deportivas; además, puede disminuir las funciones táctiles, principalmente en la onicomicosis en las manos. Es posible que el efecto emocional de la onicomicosis sea mayor, ocasionando vergüenza, pérdida de la confianza y de la autoestima, ansiedad y depresión. La ocupación y la situación socioeconómica son factores determinantes para estas manifestaciones, pues los pacientes con estatus socioeconómico bajo tienen mayor efecto fisiológico por las labores que desempeñan (obreros, campesinos, artesanos, entre otros); en los casos de nivel socioeconómico más alto, la condición cosmética con efecto emocional es mayor, causando repercusiones fisiológicas y estigmatización. En ambos casos se merma la calidad de vida.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Milobratovic‘ D, Jankovic‘ S, Vukicevic‘ J et al. Quality of life in patients with toenail onychomycosis, Mycoses 2013; 56(5): 543-51.

2. Warshaw EM, Foster JK, Cham PM et al. NailQoL: a quality-of-life instrument for onychomycosis, Int J Dermatol 2007; 46(12): 1279-86.

3. André J y Achten G. Onychomycosis, Int J Dermatol 1987; 26(8): 481-90.

4. Scher RK. Onychomycosis: a significant medical disorder, J Am Acad Dermatol 1996; 35(3 Pt2): S2-5.

5. Tosti A, Baran R, Piraccini BM y Fanti PA. Endonyx onychomycosis: a new modality of nail invasion by dermatophytes, Acta Derm Venereol 1999; 79(1): 52-3.

6. Hay RJ y Baran R. Onychomycosis: a proposed revision of the clinical classification, J Am Acad Dermatol 2011; 65(6): 1219-27.

7. Erös N y Károlyi Z. Onychomycosis and its impact on quality of life, Acta Microbiol Immunol Hung 2002; 49(2-3): 347-9.

8. Bonifaz A, Paredes V, Fierro L et al. Paronychia, Skinmed 2013; 11 (1): 14-6.

9. Hosuru Subramanya S, Hamal D, Nayak N y Gokhale S. Onychomycosis due to Candida parapsilosis in a child with ventricular septal defect: an unusual predisposition, Case Rep Pediatr 2016; doi: 10.1155/2016/7026068.

10. Ortega-Springall MF, Arroyo-Escalante S y Arenas R. Onycholisis and chromonychia: a case caused by Trichosporon inkin, Skin Appendage Disord 2016; 1(3): 144-6.

11. Bonifaz A, Cruz-Aguilar P y Ponce RM. Onychomycosis by molds. Report of 78 cases, Eur J Dermatol 2007; 17(1): 70-2.

12. Moreno G y Arenas R. Other fungi causing onychomycosis, Clin Dermatol 2010; 28(2): 160-3.

13. Scher RK. Onychomycosis is more than a cosmetic problem, Br J Dermatol 1994; 130(Supl 43): 15.

14. Sigurgeirsson B y Baran R. The prevalence of onychomycosis in the global population: a literature study, J Eur Acad Dermatol Venereol 2014; 28(11): 1480-91.

15. Scher RK, Tavakkol A, Sigurgeirsson B et al. Onychomycosis: diagnosis and definition of cure, J Am Acad Dermatol 2007; 56(6): 939-44.

16. Welsh O, Vera-Cabrera L y Welsh E. Onychomycosis, Clin Dermatol 2010; 28(2): 151-9.

17. Gupta AK, Gupta G, Jain HC et al. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians’ offices, J Eu Acad Dermatol Venereol 2016; 30(9): 1567-72.

18. Gupta AK, Daigle D y Foley KA. The prevalence of culture-confirmed toenail onychomycosis in at-risk patient population, J Eu Acad Dermatol Venereol 2015; 29(6): 1039-44.

19. Arenas R, Bonifaz A, Padilla MC et al. Onychomycosis. A Mexican survey”, Eu J Dermatol 2010; 20(5): 611-4.

20. Reich A y Szepietowski JC. Health-related quality of life in patients with nail disorders, Am J Clin Dermatol 2011; 12(5): 313-20.

21. Tabolli S, Alessandroni L, Gaido J et al. Health-related quality of life and nail disorders, Acta Derm Venereol 2007; 87(3): 255-9.

22. Lubeck DP, Patrick DL, McNulty P et al. Quality of life of persons with onychomycosis, Qual Life Res 1993; 2(5): 341-8.

23. Drake LA. Impact of onychomycosis on quality of life, J Am Podiatr Med Assoc 1997; 87(11): 507-11.

24. Whittman LR y Hay RJ. The impact of onychomycosis on quality of life, Clin Exp Dermatol 1997; 22(2): 87-9.

25. Drake LA, Scher RK, Smith EB et al. Effect of onychomycosis on quality of life, J Am Acad Dermatol 1998; 38: 702-4.

26. Lubeck DP. Measuring health-related quality of life in onychomycosis, J Am Acad Dermatol 1998; 38: S64-8.

27. Drake LA, Patrick DL, Fleckman P et al. The impact of onychomycosis on quality of life: development of an international onychomycosisspecific questionnaire to measure patient quality of life, J Am Acad Dermatol 1999; 41: 189-96.

28. Lubeck DP, Gause D, Schein JR et al. A health-related quality of life measure for use in patients with onychomycosis: a validation study, Qual Life Res 1999; 8(1-2): 121-9.

29. Turner RR y Testa MA. Measuring the impact of onychomycosis on patient quality of life, Qual Life Res 2000; 9(1): 39-53.

30. Shaw JW, Joish VN y Coons SJ. Onychomycosis. Health-related quality of life considerations, Pharmacoeconomics 2002; 20(1): 23-36.

31. Potter LP, Mathias SD, Raut M et al. The Onycoe-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis, Health Qual Life Outcomes 2006; 4: 50.

32. Warshaw EM, Traywick CA, Hoffman AA et al. Naildex: pilot evaluation of an onychodystrophy severity instrument, Mycoses 2008; 51(1): 14-20.

33. Vanhooteghem O, Szepetiuk G, Paurobally D y Heureux F. Chronic interdigital dermatophytic infection: a common lesion associated with potentially severe consequences, Diabetes Res Clin Pract 2011; 91(1): 23-5.

34. Bunyaratavej S, Pattanaprichakul P, Leeyaphan C et al. Onychomycosis: a study of self-recognition by patients and quality of life, Indian J Dermatol Venereol Leprol 2015; 81(3): 270-4.

35. Rich P. Special patient populations: onychomycosis in the diabetic patient, J Am Acad Dermatol 1996; 35: S10-2.

36. Szepietowski JC, Reich A, Pacan P et al. Evaluation of quality of life in patients with toenail onychomycosis by Polish version of an international onychomycosis-specific questionnaire, J Eur Acad Dermatol Venereol 2007; 21(4): 491-6.

37. Tosti A y Elewski BE. Treatment of onychomycosis with eficonazole 10% topical solution and quality of life, J Clin Aesthet Dermatol 2014; 7(11): 25-30.

38. Belyayeva E, Gregoriou S, Chalikias J et al. The impact of nail disorders on quality of life, Eur J Dermatol 2013; 23(3): 366-71.

39. Szepietowski JC y Reich A. Stigmatization in onychomycosis patients: a population-based study, Mycoses 2009; 52(4): 343-9.

40. Elewski BE. The effect of toenail onychomycosis on patient quality of life, Int J Dermatol 1997; 36(10): 754-6.

41. Gregory N. Special patient populations: onychomycosis in the hiv - positive patient, J Am Acad Dermatol 1996; 35: S13-6.

42. Drake L. Quality of life issues for patients with fungal nail infections, aids Patient Care 1995; 9(Suppl 1): S15-7.

43. Opp K. Patients’ feelings and attitudes about their nail conditions, aids Patient Care 1995; 9(Suppl 1): S18.

44. Lateur N, Mortaki A y André J. Two hundred ninety-six cases of onychomycosis in children and teenagers: a 10-year laboratory survey, Pediatr Dermatol 2003; 20(5): 385-8.

45. Vásquez-del Mercado E y Arenas R. Onychomycosis among children. A retrospective study of 233 Mexican cases, Gac Med Mex 2008; 144(1): 7-10.

46. García-Romero MT, López-Aguilar E y Arenas R. Onychomycosis in immunosuppressed children receiving chemotherapy, Pediatr Dermatol 2014; 31(5): 618-20.

47. Lipner SR y Scher RK. Onychomycosis: a small step for quality of care, Curr Med Res Opin 2016; 32(5): 865-7.

48. Elewski BE. Diagnostic techniques for confirmig onychomycosis, J Am Acad Dermatol 1996; 35: S6-9.

49. Zane LT, Chanda S, Coronado D y Del Rosso J. Antifungal agents for onychomycosis: new treatment strategies to improve safety, Dermatol Online J 2016; 22(3): 1-11.

50. Poulakos M, Grace Y, Machin J y Dorval E. Eficonazole and tavaborole: emerging antifungal alternatives for the topical treatment of onychomycosis, J Pharm Pract 2016; pii : 0897190016630904. [Consultado en línea el 25 de septiembre de 2016].

51. Gupta AK, Daigle D y Foley KA. Network meta-analysis of onychomycosis treatments, Skin Appendage Disord 2015; 1(2): 74-81.

52. Nair AB, Kim HD, Chakraborty B et al. Ungueal and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis, J Pharm Sci 2009; 98(11): 4130-40.

53. Watanabe D, Kawamura C, Masuda Y et al. Successful treatment of toenail onychomycosis with photodynamic therapy, Arch Dermatol 2008; 144(1): 19-21.

54. Gupta AK, Simpson FC y Heller DF. The future of laser in onychomycosis, J Dermatolog Treat 2016; 27(2): 167-72.

55. Lateur N. Onychomycosis: beyond cosmetic distress, J Cosmet Dermatol 2006; 5(2): 171-7.

56. Gupta AK y Studholme C. How do we measure efficacy of therapy in onychomycosis: patient, physician, and regulatory perspective, J Dermatolog Treat 2016; 1-7. [Consultado en línea el 25 de septiembre de 2016].

57. Smith EB, Stein LF, Fivenson DP y Atillasoy ES, Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet, Int J Dermatol 2000; 39(11): 861-4.

58. Firooz A, Khamesipour A y Dowlati Y,Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis, J Dermatolog Treat 2003; 14(2): 95-8.